Neesha C. Dhani

19.6k total citations · 1 hit paper
113 papers, 2.6k citations indexed

About

Neesha C. Dhani is a scholar working on Oncology, Cancer Research and Reproductive Medicine. According to data from OpenAlex, Neesha C. Dhani has authored 113 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Oncology, 51 papers in Cancer Research and 28 papers in Reproductive Medicine. Recurrent topics in Neesha C. Dhani's work include Cancer Genomics and Diagnostics (37 papers), Ovarian cancer diagnosis and treatment (28 papers) and Pancreatic and Hepatic Oncology Research (27 papers). Neesha C. Dhani is often cited by papers focused on Cancer Genomics and Diagnostics (37 papers), Ovarian cancer diagnosis and treatment (28 papers) and Pancreatic and Hepatic Oncology Research (27 papers). Neesha C. Dhani collaborates with scholars based in Canada, United States and United Kingdom. Neesha C. Dhani's co-authors include David W. Hedley, Malcolm J. Moore, Michael Milosevic, Eileen M. O’Reilly, Joerg Schwock, Anthony Fyles, Daniel J. Renouf, Steven Gallinger, George A. Fisher and Yin Yang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Neesha C. Dhani

102 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma

2019 480 citations Neesha C. Dhani et al. profile →

Peers

Neesha C. Dhani

ONCOL

PRM

IMMUN

Renaud Sabatier France

Ricardo H. Álvarez United States

John W. Moroney United States

Ruth Perets Israel

Morten Mau‐Sørensen Denmark

Valentina Boni Spain

Ashley Cimino‐Mathews United States

Debora Fumagalli Belgium

Sami Diab United States

Wael A. Harb United States

Renaud Sabatier France

Neesha C. Dhani

1.4k ×0.7

ONCOL

645 ×0.7

675 ×0.9

529 ×1.2

PRM

394 ×1.3

IMMUN

Citations per year, relative to Neesha C. Dhani Neesha C. Dhani (= 1×) peers Renaud Sabatier

Countries citing papers authored by Neesha C. Dhani

Since Specialization

Citations

This map shows the geographic impact of Neesha C. Dhani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neesha C. Dhani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neesha C. Dhani more than expected).

Fields of papers citing papers by Neesha C. Dhani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neesha C. Dhani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neesha C. Dhani. The network helps show where Neesha C. Dhani may publish in the future.

Co-authorship network of co-authors of Neesha C. Dhani

This figure shows the co-authorship network connecting the top 25 collaborators of Neesha C. Dhani. A scholar is included among the top collaborators of Neesha C. Dhani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neesha C. Dhani. Neesha C. Dhani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Weaver, Alice N., Wade T. Iams, Jong Chul Park, et al.. (2024). Final outcomes analysis of the cell product SQZ‐PBMC‐HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration. Molecular Carcinogenesis. 63(8). 1421–1428. 2 indexed citations

Katzberg, Hans, Vera Bril, Warren Mason, et al.. (2024). Myasthenia Gravis in Patients Treated With Immune Checkpoint Inhibitors. JTO Clinical and Research Reports. 6(5). 100772–100772.

Dhani, Neesha C., Wang Li, Robert C. Grant, et al.. (2024). 763P Re-VOLVE: Phase II trial in women with ovarian cancer progressing post-PARP-inhibitor with treatment adapted to real-time assessment of evolving genomic resistance. Annals of Oncology. 35. S577–S578. 1 indexed citations

Lheureux, Stéphanie, Taymaa May, Michelle Wilson, et al.. (2024). Phase II randomized multi-centre study of neoadjuvant olaparib in patients with platinum sensitive relapsed high grade serous ovarian cancer: The NEO trial.. Journal of Clinical Oncology. 42(16_suppl). 5506–5506. 1 indexed citations

Snow, Stephanie, Christine Brezden‐Masley, Michael D. Carter, et al.. (2024). Barriers and Unequal Access to Timely Molecular Testing Results: Addressing the Inequities in Cancer Care Delays across Canada. Current Oncology. 31(3). 1359–1375. 12 indexed citations

Han, Kathy, Anthony Fyles, Jennifer Croke, et al.. (2022). A Phase II Randomized Trial of Chemoradiation with or without Metformin in Locally Advanced Cervical Cancer. Clinical Cancer Research. 28(24). 5263–5271. 20 indexed citations

Lee, Yeh Chen, Valerie Bowering, Sarah E. Ferguson, et al.. (2022). Management of Malignant Bowel Obstruction. Journal of Nursing Care Quality. 38(1). 69–75.

Doherty, Mark, Vincent C. Tam, Mairéad G. McNamara, et al.. (2022). Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer. British Journal of Cancer. 127(8). 1473–1478. 7 indexed citations

Baranda, Joaquina, Monica Mita, Wade T. Iams, et al.. (2021). 48MO SQZ-PBMC-HPV-101: Preliminary results of a first-in-human, dose-escalation study of a cell-based vaccine in HLA A*02+ patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors. Annals of Oncology. 32. S1393–S1393. 1 indexed citations

10.

Garg, Swati, Naïri Tchrakian, Blaise Clarke, et al.. (2021). Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series. Gynecologic Oncology Reports. 36. 100729–100729. 1 indexed citations

11.

Lheureux, Stéphanie, Ana Oaknin, Swati Garg, et al.. (2020). EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression. Clinical Cancer Research. 26(16). 4206–4215. 95 indexed citations

12.

Jiang, Di, Alejandro Berlín, Lesley Moody, et al.. (2020). Transitioning to a New Normal in the Post-COVID Era. Current Oncology Reports. 22(7). 73–73. 12 indexed citations

13.

Bavi, Prashant, Dianne Chadwick, Neesha C. Dhani, et al.. (2019). Developing a pan-cancer research autopsy programme. Journal of Clinical Pathology. 72(10). 689–695. 8 indexed citations

14.

Doherty, Mark, Mairéad G. McNamara, Priya Aneja, et al.. (2017). Long term responders to palliative chemotherapy for advanced biliary tract cancer. Journal of Gastrointestinal Oncology. 8(2). 352–360. 13 indexed citations

15.

Spreafico, Anna, Amit M. Oza, Blaise Clarke, et al.. (2017). Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC). Gynecologic Oncology. 144(2). 250–255. 21 indexed citations

16.

Yeung, Ivan, Douglass Vines, Ur Metser, et al.. (2016). Measurement of Tumor Hypoxia in Patients with Advanced Pancreatic Cancer Based on ¹⁸F-Fluoroazomyin Arabinoside Uptake. Journal of Nuclear Medicine. 57(3). 361–366. 38 indexed citations

17.

Santos, Gilda da Cunha, Neesha C. Dhani, Dongsheng Tu, et al.. (2010). Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer. Cancer. 116(24). 5599–5607. 117 indexed citations

18.

Schwock, Joerg, Neesha C. Dhani, Jinzi Zheng, et al.. (2009). Targeting Focal Adhesion Kinase with Dominant-Negative FRNK or Hsp90 Inhibitor 17-DMAG Suppresses Tumor Growth and Metastasis of SiHa Cervical Xenografts. Cancer Research. 69(11). 4750–4759. 32 indexed citations

19.

Schwock, Joerg, Neesha C. Dhani, & David W. Hedley. (2009). Targeting focal adhesion kinase signaling in tumor growth and metastasis. Expert Opinion on Therapeutic Targets. 14(1). 77–94. 87 indexed citations

20.

Pham, Nhu‐An, Trevor Do, Joerg Schwock, et al.. (2008). Activation of Src and Src‐associated signaling pathways in relation to hypoxia in human cancer xenograft models. International Journal of Cancer. 124(2). 280–286. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact